Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
Aliso Viejo, CA, August 13, 2007 - Ambry Genetics, a leader in comprehensive genetic testing, has introduced the first clinically-available genetic test for mutations causing Idiopathic Pulmonary Fibrosis (IPF), an incurable lung disease affecting approximately 128,000 people in the U.S.
Previously, all causes of IPF were unknown. Recent research published by groups based at Johns Hopkins University, Vanderbilt University, and University of Texas Southwestern Medical Center showed that mutations in two genes, TERT and TERC, account for about 10% of familial cases of Idiopathic Pulmonary Fibrosis and a low percentage of sporadic cases. The Ambry Test: IPF Telomerase includes full gene sequencing of both genes and is currently available to patients with symptoms of IPF or the related broader group of interstitial lung diseases.
"We’re grateful to Ambry for their investment into IPF research, and for making this test available to patients. The CPF encourages patients, especially those with a suspected familial connection to Idiopathic Pulmonary Fibrosis, to discuss this new test and its potential importance with their pulmonologist," said Mark Shreve, Chief Executive Officer of the Coalition for Pulmonary Fibrosis, a non-profit organization that provides education, support, and advocacy for the IPF community, and funds emerging research. "We look forward to continuing our collaboration with Ambry to support their efforts in advancing research into this devastating disease"
Ambry Genetics has a long-standing commitment to pulmonary medicine and to assisting physicians and clinical researchers in the application and interpretation of genetics for their patients. The Ambry Test: IPF Telomerase is the most recent addition to a rapidly-growing menu of diagnostic services in cystic fibrosis, alpha-1-antitrypsin, surfactant dysfunction, and other diseases.
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com